Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NXN-462
- Development stage
- Phase 2
- Lead developer
- Knight Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NXN-462 is an orally available, small molecule drug that acts as a selective inhibitor of neuronal nitric oxide synthase (nNOS). It was initially developed by NeurAxon Pharma for the treatment of neuropathic pain syndromes, including postherpetic neuralgia and migraine. The mechanism of action involves inhibition of nNOS, which plays a role in pain signaling pathways in the nervous system. Clinical development reached up to phase 2 trials for postherpetic neuralgia and phase 1 for migraine before being discontinued. There are no approved indications or known brand names associated with this compound[1][2][3][4].
02
Targets
NOS1 (nNOS)
Beyond the preview
Go deeper on NXN-462.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NXN-462.